VICTORIA, British Columbia March 4, 2020 – Optimizing Medtech Founder Value written by StarFish Medical Founder and CEO, Scott Phillips, is featured in the March 2020 print and online editions of Medical Product Outsourcing (MPO) magazine. In the article Phillips uses publicly available data on 24 medical device companies that had gone public (assembled by H. Lebret) to test his hypotheses.
“Many medical device companies we’ve worked with over the last 20 years have experienced significant outcomes. The founders did well in some cases, and in others, not so well. I wondered whether there was some predictable pattern to the outcomes. Could we act to help founders do better? Would optimizing valuation at seed and A rounds minimize founder dilution for better outcomes?”
Subheaded “Would optimizing valuation at seed and A rounds minimize founder dilution for better outcomes?“, Phillips examines 24 companies and the outcomes the founders achieved, A-round dilution, and ratio of IPO value to total investment
Phillips concludes: “This data set seems to say if there’s enough power in the value proposition and market fit, it overcomes issues of dilution, total capital required, time to market, and even early founder dilution.”
Empowering Medtech Innovation ™
About Scott Phillips
Scott Phillips is CEO of the StarFish group of companies, including StarFish Medical and ViVitro Labs Inc. He holds a degree in Engineering Physics from the University of British Columbia. Under his leadership StarFish has grown into a diverse professional organization with clients around the world and a 100% focus on medical devices. Scott is a Fellow of The Canadian Academy of Engineering, winner of the EY Entrepreneur Of The Year™ 2017 Pacific Awards Technology category, 2017 recipient of the VIATEC Technology Champion award, Chairman of the LifeSciences British Columbia board, and volunteers with Junior Achievement, Entrepreneurs Organization, and University of British Columbia. In September 2019, StarFish Medical placed in both The Globe and Mail’s ranking of Canada’s Top Growing Companies and Canadian Business and Maclean’s 2019 Growth 500 list.
About the 100 x 100 Initiative
StarFish Medical launched the 100 x 100 initiative at Medical Device Playbook 2018 in Toronto. 100 x 100 highlights client products and companies that achieve $100 million in revenue or valuation. The program recognizes and encourages the important financial impact that innovative design and commercialization process can make on client products and companies. StarFish Medical employees aim to help 100 companies or products achieve the $100 million goal within the next 10 years.
About StarFish Medical
StarFish Medical is a full service Medical Device Design company offering design, development, and manufacturing services based in Toronto and Victoria. We use our Pathfinder™ process to reduce wasted effort and increase success for medical device product definition, technical engineering, and product development. Prototype and volume production are delivered within an ISO 13485 certified Quality Management System and an FDA registered manufacturing and clean room facility. www.starfishmedical.com
StarFish Medical media contact: